Prof. UĞUR ÖZBEK

Personal Information

Office Phone: +90 216 500 4309
Email: ugur.ozbek@acibadem.edu.tr
Web: https://avesis.acibadem.edu.tr/ugur.ozbek

International Researcher IDs
ScholarID: VxukIlUAAAAJ
ORCID: 0000-0001-5319-0547
Publons / Web Of Science ResearcherID: C-9513-2017
Yoksis Researcher ID: 167476

Education Information

Expertise In Medicine, Istanbul University, Cerrahpaşa Tıp Fakültesi, Turkey 2015 - 2019
Doctorate, Istanbul University, Health Sciences Institute, Turkey 1989 - 1994
Undergraduate, Istanbul University, Cerrahpaşa Tıp Fakültesi, Cerrahpaşa Tıp Pr., Turkey 1979 - 1986

Dissertations

Doctorate, Nöroblastom'da N-myc Onkogen Amplification ve klinik önemi, Istanbul University, Sağlık Bilimleri Enstitüsü, 1994

Academic Titles / Tasks

Professor, Acibadem Mehmet Ali Aydinlar University, Vocational School Of Health Services, 2016 - Continues
Professor, Istanbul University, Deneysel Tıp Araştırma Enstitüsü, Genetik Anabilim Dalı, 2003 - Continues
Professor, Erasmus Universiteit Rotterdam, Erasmus Medical Faculty, Erasmus Medical Center, 2006 - 2007
Research Assistant, University of Tennessee, Memphis, St. Jude Children's Rerearch Hospital, Genetics Department, 1998 - 2000

Academic and Administrative Experience

Head of Department, Acibadem Mehmet Ali Aydinlar University, Graduate School Of Health Sciences, Translasyonel Tıp Anabilim Dalı, 2022 - Continues
Head of Department, Acibadem Mehmet Ali Aydinlar University, Graduate School Of Health Sciences, Department Of Genomic Studies, 2021 - Continues
University Executive Board Member, Acibadem Mehmet Ali Aydinlar University, Administrative Departments, 2018 - Continues
Director of the Center, Acibadem Mehmet Ali Aydinlar University, Additional Departments, 2017 - Continues
Head of Department, Acibadem Mehmet Ali Aydinlar University, School Of Medicine, Department Of Medical Sciences, 2016 - Continues
Director of The Institution, Acibadem Mehmet Ali Aydinlar University, 2016 - 2022
Istanbul University, 2010 - 2016

Courses

Thesis planning and management, Doctorate, 2022 - 2023
Diabetes Genetics, Undergraduate, 2022 - 2023
Neurogenetics, Undergraduate, 2022 - 2023
GIS Diseases genetics, Undergraduate, 2021 - 2022
Project planning and management, Doctorate, 2021 - 2022
Hematological Malignancies, Undergraduate, 2021 - 2022

Advising Theses

Özbek U., Yaygın değişken immün yetersizlik (CVID) hastalarında CD19, ICOS, TACI, BAFF-R gen mutasyonlarının araştırılması, Postgraduate, S.SISKO(Student), 2016
Özbek U., Çocukluk çağı nüks akut lösemi hastalarında tüm genom analizleri, Doctorate, Y.ERBİLGİN(Student), 2015
Özbek U., Ailesel geçiş gösteren idiyopatik epilepsilerin genetik altyapısının aydınlatılması, Doctorate, F.NUR(Student), 2014
Özbek U., Stem-loop RT-polimeraz zincir reaksiyonu (PZR) yöntemi ile mikro RNA (miRNA) gen anlatım farklılıklarının tespiti, Postgraduate, N.MAVİ(Student), 2013
Özbek U., T-hücreli akut lenfoblastik lösemide genom boyu anlatım analizleri, Doctorate, Ö.HATIRNAZ(Student), 2012
Özbek U., T hücreli akut lenfoblastik lösemili hastalarda mikroRNA (miRNA) anlatımının tespiti, Postgraduate, C.ÖZTUNÇ(Student), 2012
Özbek U., İdiyopatik jeneralize epilepsili ailelerde lokus ve gen analizi, Postgraduate, İ.KARACAN(Student), 2012
Özbek U., Mezyal temporal lob epilepsisinde apoptoza yol açan genlerin ekspresyonlarının analizi, Postgraduate, E.YÜCESAN(Student), 2011
Özbek U., B hücreli akut lenfoblastik lösemilerde PAX5 geninin araştırılması, Postgraduate, S.ÖZDEMİRLİ(Student), 2010
Özbek U., Temporal lob epilepsi patogenezinde enflamasyonla ilgili genlerin ekspresyonlarının araştırılması, Postgraduate, Ö.ÖZDEMİR(Student), 2010
Özbek U., PINK1 Ve SWAP70 genlerinin klonlanmasıyla oluşturulan proteinlerin behçet hastalarında ELISA yöntemi ile taranması, Postgraduate, E.UĞUREL(Student), 2009
Özbek U., Temporal lob epileptogeneziyle ilişkili genlerin ekspresyon analizi, Doctorate, N.BEBEK(Student), 2009
Özbek U., Çocukluk çağı akut myeloid lösemi hastalarında kromozomal değişiklikler ve FLT3 geni mutasyonlarının araştırılması, Postgraduate, E.MEHMET(Student), 2008
Özbek U., T-ALL hastalarında NOTCH1 mutasyonunun araştırılması, Postgraduate, Y.ERBİLGİN(Student), 2008
Özbek U., Akut myeloid lösemi etiyolojisinde MN1 geninin rolü, Doctorate, S.SIRMA(Student), 2007
Özbek U., Behçet hastalığında rol alan yeni immunogenetik antijenlerin SEREX metodu ile belirlenmesi, Doctorate, B.VURAL(Student), 2005
Özbek U., CYP1A1, CYP2D6, CYP2E1, GSTT1 ve GSTM1 gen polimorfizmlerinin akut lösemi etiyolojisindeki rollerinin saptanması, Doctorate, M.AYDIN(Student), 2003
Özbek U., Sitokin gen polimorfizmlerinin hematopoetik kök hücre nakli sonrası graft-versus-host hastalığı ile ilişkisi, Postgraduate, N.GÜRSES(Student), 2003
Özbek U., Çocukluk çağı obesitesinde glukokortikoid reseptör gen polimorfizminin bazı somatik ve biyokimyasal parametrelerle ilişkisi, Postgraduate, N.ŞEN(Student), 2002
Özbek U., Medüller tiroid karsinomlu olgularda RET (REarranged during transfection) proto-onkogen mutasyonları, Postgraduate, N.BİÇER(Student), 1999
Özbek U., Çocukluk çağı akut lenfoblastik lösemilerinde TEL-AML1 (Translocation Ets Leukemia-Acute Myeloid Leukemia 1) füzyon geni tespiti ve prognostik önemi, Postgraduate, S.SIRMA(Student), 1999

Published journal articles indexed by SCI, SSCI, and AHCI

I. **Betulin Stimulates Osteogenic Differentiation of Human Osteoblasts-Loaded Alginate-Gelatin Microbeads**
Karaca M. A., Kancagi D. D., Ozbek U., Ovali E., GÖK ÖZATAY Ö.
BIOENGINEERING-BASEL, no.6, 2024 (SCI-Expanded)

II. **Impact of TP53 gene variants on prognosis and survival of childhood acute lymphoblastic leukemia.**
Firtina S., Erbilgin Y., Hatirnaz Ng Ö., Karaman S., Karakas Z., Celkan T. T., Gelen S. A., Yildirmak Y., Ozbek U., Sayitoglu M.
Scandinavian journal of clinical and laboratory investigation, vol.83, no.3, pp.187-193, 2023 (SCI-Expanded)

III. **Perception and management of cancer predisposition in pediatric cancer centers: A European-wide questionnaire-based survey.**
Lazic J., Haas O. A., Özbek U., Ripperger T., Byrjalsen A., Te Kronnie G., Sayitoğlu M., Ng Ö., Agaoglu N. B., Erbilgin Y., et al.
Pediatric blood & cancer, vol.70, no.5, 2023 (SCI-Expanded)

IV. **Preparation of Cell-Loaded Microbeads as Stable and Injectable Delivery Platforms for Tissue Engineering.**
Karaca M. A., Kançağı D., Ozbek U., Ovali E., Gök Ö.
Biomimetics (Basel, Switzerland), vol.8, no.2, 2023 (SCI-Expanded)

V. **Association of mtDNA Copy Number Variations with Neoadjuvant in Triple Negative Breast Cancer Patients**
Manto K., Yilmaz S. U., PALA KARA Z., URAS C., TOKAT F., İNCE Ü., MÜFTÜOĞLU M., Ozbek U.
BREAST, 2023 (SCI-Expanded)

VI. **Obstacles and expectations of rare disease patients and their families in Turkiye: ISTisNA project survey results**
Hatirnaz Ng Ö., Sahin I., Erbilgin Y., Ozdemir O., Yucesan E., Erturk N., Yemenici M., Akgun Dogan Ö., Ugur Iseri S. A., Satman I., et al.
FRONTIERS IN PUBLIC HEALTH, vol.10, 2023 (SCI-Expanded)

VII. **Undiagnosed diseases: Needs and opportunities in 20 countries participating in the Undiagnosed Diseases Network International**
Taruscio D., Salvatore M., Lumaka A., Carta C., Cellai L. L., Ferrari G., Sciascia S., Groft S., ALANAY Y., Azam M., et al.
FRONTIERS IN PUBLIC HEALTH, vol.11, 2023 (SCI-Expanded)

VIII. **Clinical and genetic analyses in syndromic intellectual disability with primary microcephaly reveal biallelic and de novo variants in patients with parental consanguinity**
Mercan S., Akcakaya N. H., Salman B., Yapici Z., ÖZBEK U., UĞUR İŞERİ S. A.
Genes and Genomics, vol.45, no.1, pp.13-21, 2023 (SCI-Expanded)

IX. **Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement**
Aytaç E., Özer L., Baca B., Balık E., Kapran Y., Taşkın O. C., Oyan Uluç B., Abacıoğlu M. U., Gönenç M., Bölükbaşı Y., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.33, no.8, pp.627-663, 2022 (SCI-Expanded)

X. **Determining T and B Cell development by TREC/KREC analysis in primary immunodeficiency patients and healthy controls**
Senturk G., Ng Y. Y., Eltan S. B., Baser D., Ogulur I., Altindirek D., Firtina S., Yilmaz H., Kocamis B., Kiykim A., et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol.95, 2022 (SCI-Expanded)

XI. **Primary antibody deficiencies in Turkey: molecular and clinical aspects**
Firtina S., Ng Y. Y., HATIRNAZ NG Ö., Kiykim A., Ozek E. Y., Kara M., AYDINER E., Nepesov S., Camcioglu Y., Sayar E. H., et al.
IMMUNOLOGIC RESEARCH, vol.70, no.1, pp.44-55, 2022 (SCI-Expanded)

XII. **Mutational landscape of SARS-CoV-2 genome in Turkey and impact of mutations on spike protein structure.**
Hatirnaz N., Akyoney S., Sahin I., Soykam H., Bayram A., Ozdemir Ö., Kancagi D., Sir K., Yurtsever B., Kocagoz A., et al.
PloS one, vol.16, no.12, 2021 (SCI-Expanded)

XIII. **The rare rs769301934 variant in NHLRC1 is a common cause of Lafora disease in Turkey.**

Haryanyan G., Ozdemir Ö., Tutkavul K., Dervent A., Ayta S., Ozkara C., Salman B., YÜCESAN E., Kesim Y., SÜSGÜN S., et al.
Journal of human genetics, vol.66, no.12, pp.1145-1151, 2021 (SCI-Expanded)

XIV. **Prognostic evidence of LEF1 isoforms in childhood acute lymphoblastic leukemia.**
ERBİLGİN Y., Ng Ö., Can I., Firtina S., Kucukcankurt F., KARAMAN S., KARAKAŞ Z., Celkan T. T., ZENGİN E., AYLAN GELEN S., et al.
International journal of laboratory hematology, vol.43, no.5, pp.1093-1103, 2021 (SCI-Expanded)

XV. **Bağlantı ve Tüm Ekzom Dizileme Analizlerinin Birlikte Değerlendirilmesiyle CIC Geninin İzole Distoni Adayı Olarak Belirlenmesi**
Salman B., YÜCESAN E., SAMANCI B., BİLGİÇ B., HANAĞASI H. A., GÜRVİT İ. H., ÖZBEK U., UĞUR İŞERİ S. A.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI, vol.84, pp.457-463, 2021 (SCI-Expanded)

XVI. **Gamma-irradiated SARS-CoV-2 vaccine candidate, OZG-38.61.3, confers protection from SARS-CoV-2 challenge in human ACEII-transgenic mice.**
Turan R. D., Tastan C., Kancagi D. D., Yurtsever B., Karakus G. S., Ozer S., Abanuz S., Cakirsoy D., TÜMENTEMUR G., Demir S., et al.
Scientific reports, vol.11, no.1, pp.15799, 2021 (SCI-Expanded)

XVII. **Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates**
Sir Karakus G., Tastan C., Dilek Kancagi D., Yurtsever B., Tumentemur G., Demir S., Turan R. D., Abanuz S., Cakirsoy D., Seyis U., et al.
SCIENTIFIC REPORTS, vol.11, no.1, 2021 (SCI-Expanded)

XVIII. **Mutational landscape of severe combined immunodeficiency patients from Turkey**
Çekiç Ş., Ng Y. Y., Ng Ö., Kıykım A., Özen A. O., Özen A. O., Özen A. O., Özen A. O., Özen A. O., Torun S. H., et al.
INTERNATIONAL JOURNAL OF IMMUNOGENETICS, vol.47, no.6, pp.529-538, 2020 (SCI-Expanded)

XIX. **Copy-number variations in adult patients with chronic immune thrombocytopenia.**
YÜCESAN E., Ng Ö., Yalniz F. F., Yilmaz H., SALİHOĞLU A., Sudutan T., Eskazan A. E., Ongoren S., Baslar Z., Soysal T., et al.
Expert review of hematology, vol.13, no.11, pp.1277-1287, 2020 (SCI-Expanded)

XX. **Hydrogen Sulphide and Nitric Oxide Cooperate in Cardioprotection Against Ischemia/Reperfusion Injury in Isolated Rat Heart.**
ÜSTÜNOVA S., TAKIR S., YILMAZER N., Bulut H., ALTINDİREK D., HATIRNAZ NG Ö., Tansel C. D., Dogan B. S. U., ÖZBEK U., ARMUTAK E. İ., et al.
In vivo (Athens, Greece), vol.34, no.5, pp.2507-2516, 2020 (SCI-Expanded)

XXI. **The Impact and Prognostic Significance of Chronic Lymphocytic Leukemia Upregulated 1 (CLLU1) Gene Expression in Patients with Chronic Lymphocytic Leukemia: A Single Center Experience**
Sevinc M., Karabulut A., Eskazan A. E., Tatonyan S. C., ÖZBEK U., Soysal T.
LABORATORY MEDICINE, vol.51, no.3, pp.259-264, 2020 (SCI-Expanded)

XXII. **PTEN and AKT1 Variations in Childhood T-Cell Acute Lymphoblastic Leukemia**
Kucukcankurt F., Erbilgin Y., Firtina S., Hatirnaz Ö., Karakas Z., Celkan T., Unuvar A., Ozbek U., Sayitoglu M.
TURKISH JOURNAL OF HEMATOLOGY, vol.37, no.2, pp.98-103, 2020 (SCI-Expanded)

XXIII. **Association of genetic variants with colorectal cancer in the extended MENA region: A systematic review.**
Sidenna M., Bux R., Fadl T., Ozbek U., Zayed H.
Current molecular medicine, 2019 (SCI-Expanded)

XXIV. **Homozygous c.130-131 ins A (pW44X) mutation in the HAX1 gene as the most common cause of congenital neutropenia in Turkey: Report from the Turkish Severe Congenital Neutropenia Registry.**
YILMAZ KARAPINAR D., PATIROĞLU T., Metin A., Caliskan U., CELKAN T. T., YILMAZ B., KARAKAŞ Z., Karapinar T. H., Akinci B., Ozkinay F., et al.
Pediatric blood & cancer, vol.66, no.10, 2019 (SCI-Expanded)

XXV. **Prognostic gene alterations and clonal changes in childhood B-ALL.**

ERBİLGİN Y., Firtina S., Mercan S., Ng Ö., KARAMAN S., Tasar O., KARAKAŞ Z., Celkan T. T., Zenging E., Sarperg N., et al.
Leukemia research, vol.83, pp.106159, 2019 (SCI-Expanded)

XXVI. **Dealing with the gray zones in the management of gastric cancer: The consensus statement of the Istanbul Group**
AYTAÇ E., Aslan F., ÇİÇEK B., Erdamar S., Gurses B., GÜVEN K., Falay O., KARAHASANOĞLU T., Selcukbiricik F., Selek U., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, no.7, pp.584-598, 2019 (SCI-Expanded)

XXVII. **The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations**
Soysal T., Eskazan A. E., Serin I., Sadri S., Keskin D., Yurttas N. O., Berk S., Ozunal I. E., SALİHOĞLU A., AR M. C., et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.19, no.7, 2019 (SCI-Expanded)

XXVIII. **Biallelic loss of EEF1D function links heat shock response pathway to autosomal recessive intellectual disability**
UĞUR İŞERİ S. A., YÜCESAN E., TUNCER KILINÇ F. N., Calik M., Kesim Y., Uzun G. A., ÖZBEK U.
JOURNAL OF HUMAN GENETICS, vol.64, no.5, pp.421-426, 2019 (SCI-Expanded)

XXIX. **No evidence for a BRD2 promoter hypermethylation inblood leukocytes of Europeans with juvenile myoclonic epilepsy**
Schulz H., Ruppert A., Zara F., Madia F., Iacomino M., Vari M. S., Balagura G., Minetti C., Striano P., Blanche A., et al.
EPILEPSIA, vol.60, no.5, 2019 (SCI-Expanded)

XXX. **A Novel and Mosaic WDR45 Nonsense Variant Causes Beta-Propeller Protein-Associated Neurodegeneration Identified Through Whole Exome Sequencing and X chromosome Heterozygosity Analysis**
Akcakaya N. H., Salman B., Gormez Z., ARGÜDEN Y., ÇIRAKOĞLU A., ÇAKMUR R., DÖNMEZ ÇOLAKOĞLU B., Hacihanefioglu S., ÖZBEK U., Yapici Z., et al.
NEUROMOLECULAR MEDICINE, vol.21, no.1, pp.54-59, 2019 (SCI-Expanded)

XXXI. **Identification of epilepsy related pathways using genome-wide DNA methylation measures: A trio-based approach**
ÖZDEMİR Ö., Egemen E., UĞUR İŞERİ S. A., SEZERMAN O. U., BEBEK N., BAYKAL B., ÖZBEK U.
PLOS ONE, vol.14, no.2, 2019 (SCI-Expanded)

XXXII. **; The Role of the Local Bone Marrow Renin-Angiotensin System in Multiple Myeloma**
Sakai B., SAYİTOĞLU M., İSTEMİHAN Z., KARAN M. A., ERTEN S. N., Dogan O., ÖZBEK U., GENÇ N. S., Tascioglu C., BEŞIŞIK S.
TURKISH JOURNAL OF HEMATOLOGY, vol.36, no.3, pp.178-185, 2019 (SCI-Expanded)

XXXIII. **Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors.**
ERBİLGİN Y., Eskazan A. E., HATIRNAZ NG Ö., SALİHOĞLU A., ELVERDİ T., Firtina S., Tasar O., Mercan S., Sisko S., Khodzhaev K., et al.
Leukemia & lymphoma, vol.60, no.1, pp.200-207, 2019 (SCI-Expanded)

XXXIV. **Clinical and genetic spectrum of an orphan disease MPAN: a series with new variants and a novel phenotype**
Akcakaya N. H., Haryanyan G., Mercan S., Sozer N., Ali A., Tombul T., ÖZBEK U., Iseri S. A. U., YAPICI Z.
NEUROLOGIA I NEUROCHIRURGIA POLSKA, vol.53, no.6, pp.476-483, 2019 (SCI-Expanded)

XXXV. **Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up**
SAYDAM G., HAZNEDAROĞLU İ. C., KAYNAR L., Yavuz A., ALİ R., GÜVENÇ B., AKAY O. M., Baslar Z., ÖZBEK U., SÖNMEZ M., et al.
HEMATOLOGY, vol.23, no.10, pp.771-777, 2018 (SCI-Expanded)

XXXVI. **Investigation of SLC2A1 gene variants in genetic generalized epilepsy patients with eyelid myoclonia**
Altiokka-Uzun G., ÖZDEMİR Ö., Ugur-Iseri S., BEBEK N., Gurses C., ÖZBEK U., BAYKAL B.
EPILEPTIC DISORDERS, vol.20, no.5, pp.396-400, 2018 (SCI-Expanded)

XXXVII. **Rare coding variants in genes encoding GABA(A) receptors in genetic generalised epilepsies: an exome-based case-control study**
May P., Girard S., Harrer M., Bobbili D. R., Schubert J., Wolking S., Becker F., Lachance-Touchette P., Meloche C., Gravel M., et al.
LANCET NEUROLOGY, vol.17, no.8, pp.699-708, 2018 (SCI-Expanded)

XXXVIII. **Clinical phenotype of hereditary spastic paraplegia due to KIF1C gene mutations across life span**
Yucel-Yilmaz D., YÜCESAN E., YALNIZOĞLU D., Oguz K. K., Sagiroglu M. S., ÖZBEK U., SERDAROĞLU E., BİLGİÇ B., Erdem S., UĞUR İŞERİ S. A., et al.
BRAIN & DEVELOPMENT, vol.40, no.6, pp.458-464, 2018 (SCI-Expanded)

XXXIX. **Association of Pro-apoptotic Bad Gene Expression Changes with Benign Thyroid Nodules**
GÜL N., Temel B., Ustek D., SIRMA EKMEKCİ S., Kapran Y., TUNCA F., ŞENYÜREK Y., ÖZBEK U., Alagol F.
IN VIVO, vol.32, no.3, pp.555-559, 2018 (SCI-Expanded)

XL. **Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.**
Saydam G., Haznedaroglu I., Kaynar L., Yavuz A., Ali R., Guvenc B., Akay O., Baslar Z., Ozbek U., Sonmez M., et al.
Hematology (Amsterdam, Netherlands), pp.1-7, 2018 (SCI-Expanded)

XLI. **Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature**
Ongoren S., Eskazan A. E., Suzan V., Savci S., Ozunal I. E., Berk S., Yalniz F. F., ELVERDİ T., Salihoglu A., ERBİLGİN Y., et al.
HEMATOLOGY, vol.23, no.4, pp.212-220, 2018 (SCI-Expanded)

XLII. **Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec**
Eskazan A. E., Sadri S., Keskin D., Ayer M., Kantarcioglu B., Demirel N., Aydin D., Aydinli F., Yokus O., Ozunal I. E., et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.17, no.12, pp.804-811, 2017 (SCI-Expanded)

XLIII. **SYNE1 related cerebellar ataxia presents with variable phenotypes in a consanguineous family from Turkey**
YÜCESAN E., UĞUR İŞERİ S. A., BİLGİÇ B., Gormez Z., GÜNGÖR B., Sarac A., ÖZDEMİR Ö., Sagiroglu M., GÜRVİT İ. H., HANAĞASI H. A., et al.
NEUROLOGICAL SCIENCES, vol.38, no.12, pp.2203-2207, 2017 (SCI-Expanded)

XLIV. **A novel pathogenic frameshift variant of CD3E gene in two T-B+ NK+ SCID patients from Turkey.**
Firtina S., Ng Y. Y., Ng Ö., Nepesov S., Yesilbas O., Kilercik M., Burtecene N., Cinar S., Camcioglu Y., ÖZBEK U., et al.
Immunogenetics, vol.69, no.10, pp.653-659, 2017 (SCI-Expanded)

XLV. **Clinical and genetic features of PKAN patients in a tertiary centre in Turkey.**
Akcakaya N. H., Iseri S. U., Bilir B., Battaloglu E., Tekturk P., GÜLTEKİN M., Akar G., Yigiter R., Hanagasi H., Alp R., et al.
Clinical neurology and neurosurgery, vol.154, pp.34-42, 2017 (SCI-Expanded)

XLVI. **Aberrant Hypermethylation of APC Tumor Supressor Gene in Acute Leukemia Patients**
Hatirnaz O. N. G., Firtina S., Erbilgin Y., Özbek U., Sayitoglu M.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, vol.27, pp.1-7, 2017 (SCI-Expanded)

XLVII. **Dysregulation of the DKK1 gene in pediatric B-cell acute lymphoblastic leukemia**
Firtina S., Hatirnaz Ng Ö., Erbilgin Y., Ozbek U., Sayitoglu M.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.47, no.1, pp.357-363, 2017 (SCI-Expanded)

XLVIII. **Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase**
SAYDAM G., HAZNEDAROĞLU İ. C., KAYNAR L., Yavuz A., ALİ R., GÜVENÇ B., AKAY O. M., Baslar Z., ÖZBEK U., SÖNMEZ M., et al.
EXPERT OPINION ON PHARMACOTHERAPY, vol.17, no.14, pp.1851-1858, 2016 (SCI-Expanded)

XLIX. **Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia**
Simsek E. T., Eskazan A. E., Cengiz M., AR M. C., Ekizoglu S., Salihoglu A., Gulturk E., ELVERDİ T., Aydin S. O., DEMİRÖZ

A. S., et al.
JOURNAL OF CLINICAL PATHOLOGY, vol.69, no.9, pp.810-816, 2016 (SCI-Expanded)

L. **A novel gene mutation in PANK2 in a patient with severe jaw-opening dystonia.**
Yapici Z., Akcakaya N. H., Tekturk P., Iseri S. A. U., Ozbek U.
Brain & development, vol.38, no.8, pp.755-8, 2016 (SCI-Expanded)

LI. **Screening LGI1 in a cohort of 26 lateral temporal lobe epilepsy patients with auditory aura from Turkey detects a novel de novo mutation**
Kesim Y. F., Uzun G. A., YÜCESAN E., TUNCER KILINÇ F. N., ÖZDEMİR Ö., BEBEK N., ÖZBEK U., UĞUR İŞERİ S. A., BAYKAL B.
EPILEPSY RESEARCH, vol.120, pp.73-78, 2016 (SCI-Expanded)

LII. **The frequency of C609T polymorphism in the NQO1 gene and its relation to cytogenetic abnormalities in patients with myelodysplastic syndrome**
Bagatir G., Sirma S., PALANDUZ Ş., ÖZTÜRK Ş., ÇEFLE K., ÖZBEK U., YENEREL M. N., NALÇACI M.
CELLULAR AND MOLECULAR BIOLOGY, vol.62, no.7, pp.61-65, 2016 (SCI-Expanded)

LIII. **Investigation of the possible association of NEDD4-2 (NEDD4L) gene with idiopathic photosensitive epilepsy**
Vanli-Yavuz E. N., ÖZDEMİR Ö., Demirkan A., Catal S., BEBEK N., ÖZBEK U., BAYKAL B.
ACTA NEUROLOGICA BELGICA, vol.115, no.3, pp.241-245, 2015 (SCI-Expanded)

LIV. **High MN1 expression increases the in vitro clonogenic activity of primary mouse B-cells**
Numata M., YENER M. D., SIRMA EKMEKCİ S., Aydin M., Grosveld G., Cardone M., Terranova S., Geltink R. K., ÖZBEK U., Ozcelik E., et al.
LEUKEMIA RESEARCH, vol.39, no.8, pp.906-912, 2015 (SCI-Expanded)

LV. **A clinical variant in SCN1A inherited from a mosaic father cosegregates with a novel variant to cause Dravet syndrome in a consanguineous family**
TUNCER KILINÇ F. N., Gormez Z., Calik M., Uzun G. A., Sagiroglu M. S., Yuceturk B., Yuksel B., BAYKAL B., BEBEK N., Iscan A., et al.
EPILEPSY RESEARCH, vol.113, pp.5-10, 2015 (SCI-Expanded)

LVI. **herg1b Expression as a Potential Specific Marker in Pediatric Acute Myeloid Leukemia Patients with HERG 897K/K Genotype**
Erdem M., Tekiner T. A., Fejzullahu A., Akan G., Anak S., Saribeyoglu E. T., ÖZBEK U., ATALAR F.
PEDIATRIC HEMATOLOGY AND ONCOLOGY, vol.32, no.3, pp.182-192, 2015 (SCI-Expanded)

LVII. **A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR**
White H., Deprez L., Corbisier P., Hall V., Lin F., Mazoua S., Trapmann S., Aggerholm A., Andrikovics H., Akiki S., et al.
LEUKEMIA, vol.29, no.2, pp.369-376, 2015 (SCI-Expanded)

LVIII. **A Possible Role for WNT5A Hypermethylation in Pediatric Acute Lymphoblastic Leukemia**
HATIRNAZ NG Ö., Firtina S., Can I., KARAKAŞ Z., Agaoglu L., DOĞRU Ö., Celkan T., Akcay A., Yildirmak Y., Timur C., et al.
TURKISH JOURNAL OF HEMATOLOGY, vol.32, no.2, pp.127-135, 2015 (SCI-Expanded)

LIX. **The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia**
Eskazan A. E., ELVERDİ T., Yalniz F. F., Salihoglu A., AR M. C., Aydin S. O., Baslar Z., Aydin Y., Tuzuner N., ÖZBEK U., et al.
LEUKEMIA & LYMPHOMA, vol.55, no.12, pp.2935-2937, 2014 (SCI-Expanded)

LX. **Nilotinib Results in Improved Rates of Molecular Response in Turkish Newly Diagnosed CML-CP Patients: A 24-Month Update**
SAYDAM G., HAZNEDAROĞLU İ. C., KAYNAR L., Yavuz A., ALİ R., GÜVENÇ B., AKAY O. M., Baslar Z., ÖZBEK U., SÖNMEZ M., et al.
BLOOD, vol.124, no.21, 2014 (SCI-Expanded)

LXI. **First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate**

Eskazan A. E., Ayer M., Kantarcioglu B., Arica D., Demirel N., Aydin D., Yalniz F. F., ELVERDİ T., Salihoglu A., AR M. C., et al.
BRITISH JOURNAL OF HAEMATOLOGY, vol.167, no.1, pp.139-141, 2014 (SCI-Expanded)

LXII. **Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion**
Eskazan A. E., Eyice D., Kurt E. A., ELVERDİ T., Yalniz F. F., Salihoglu A., AR M. C., Aydin S. O., Baslar Z., Ferhanoglu B., et al.
LEUKEMIA RESEARCH, vol.38, no.7, pp.781-787, 2014 (SCI-Expanded)

LXIII. **Local Renin-Angiotensin System in Normal Hematopoietic and Multiple Myeloma-Related Progenitor Cells**
Uz B., Tatonyan S. C., Sayitoglu M., Erbilgin Y., Hatirnaz O., AKSU S., BÜYÜKAŞIK Y., SAYINALP N., GÖKER H., ÖZCEBE O. İ., et al.
TURKISH JOURNAL OF HEMATOLOGY, vol.31, no.2, pp.136-142, 2014 (SCI-Expanded)

LXIV. **Deregulated WNT signaling in childhood T-cell acute lymphoblastic leukemia**
HATIRNAZ NG Ö., ERBİLGİN Y., Firtina S., Celkan T., KARAKAŞ Z., Aydogan G., Turkkan E., Yildirmak Y., Timur C., ZENGİN E., et al.
BLOOD CANCER JOURNAL, vol.4, 2014 (SCI-Expanded)

LXV. **Parathyroid allotransplantation in rabbits without cultivation**
Can I., Aysan E., YÜCESAN E., SAYİTOĞLU M., ÖZBEK U., Ercivan M., Atasoy H., Buyukpinarbasili N., Muslumanoglu M.
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol.7, no.1, pp.280-284, 2014 (SCI-Expanded)

LXVI. **Local hematopoietic renin-angiotensin system in myeloid versus lymphoid hematological neoplastic disorders**
Uz B., Tatonyan S. C., Sayitoglu M., Erbilgin Y., Ng O. H., Buyukasik Y., Sayinalp N., Aksu S., Goker H., Ozcebe O. I., et al.
JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, vol.14, no.4, pp.308-314, 2013 (SCI-Expanded)

LXVII. **The Role of MDR1 C3435T Gene Polymorphism on Gingival Hyperplasia in Turkish Renal Transplant Patients Treated With Cyclosporine in the Absence of Calcium Channel Blockers**
Kazancioglu H. O., Ak G., Turkmen A., ÖZBEK U., Tuncer F. N., Karabulut A.
TRANSPLANTATION PROCEEDINGS, vol.45, no.6, pp.2233-2237, 2013 (SCI-Expanded)

LXVIII. **LOCAL HEMATOPOIETIC RENIN-ANGIOTENSIN SYSTEM IN MYELOID VERSUS LYMPHOID HEMATOLOGICAL NEOPLASTIC DISORDERS**
Uz B., Haznedaroglu I., Sayinalp N., Ozcebe O., Buyukasik Y., Goker H., Aksu S., Tatonyan S., Sayitoglu M., Erbilgin Y., et al.
HAEMATOLOGICA, vol.98, pp.768, 2013 (SCI-Expanded)

LXIX. **LOCAL RENIN-ANGIOTENSIN SYSTEM IN NORMAL HEMATOPOIETIC AND MULTIPLE MYELOMA-RELATED PROGENITOR CELLS**
Haznedaroglu I., Uz B., Ozcebe O., Buyukasik Y., Goker H., Aksu S., Sayinalp N., Tatonyan S., Sayitoglu M., Erbilgin Y., et al.
HAEMATOLOGICA, vol.98, pp.768, 2013 (SCI-Expanded)

LXX. **Mediastinal adipose tissue expresses a pathogenic profile of 11 β-hydroxysteroid dehydrogenase Type 1, glucocorticoid receptor, and CD68 in patients with coronary artery disease.**
ATALAR F., Gormez S., Caynak B., Akan G., Tanriverdi G., Bilgic-Gazioglu S., Gunay D., Duran C., Akpinar B., Ozbek U., et al.
Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology, vol.22, no.3, pp.183-8, 2013 (SCI-Expanded)

LXXI. **Identification of Interconnected Markers for T-Cell Acute Lymphoblastic Leukemia**
Maiorov E. G., Keskin O., Ng Ö., Ozbek U., Gursoy A.
BIOMED RESEARCH INTERNATIONAL, 2013 (SCI-Expanded)

LXXII. **Renin-Angiotensin System (RAS) Expressions in Myeloid Leukemic Cell Lines**
Uz B., Tatonyan S. C., Sayitoglu M., Erbilgin Y., Hatirnaz Ng O., BÜYÜKAŞIK Y., AKSU S., SAYINALP N., GÖKER H., ÖZCEBE O. İ., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, vol.23, no.4, pp.264-268, 2013 (SCI-Expanded)

LXXIII. **Upregulation of T-Cell-Specific Transcription Factor Expression in Pediatric T-Cell Acute Lymphoblastic Leukemia (T-ALL)**
SAYİTOĞLU M., ERBİLGİN Y., HATIRNAZ NG Ö., Yildiz I., Celkan T., Anak S., Devecioglu O., Aydogan G., Karaman S., SARPER N., et al.
TURKISH JOURNAL OF HEMATOLOGY, vol.29, no.4, pp.325-333, 2012 (SCI-Expanded)

LXXIV. **Genome-wide association analysis of genetic generalized epilepsies implicates susceptibility loci at 1q43, 2p16.1, 2q22.3 and 17q21.32**
Steffens M., Leu C., Ruppert A., Zara F., Striano P., Robbiano A., Capovilla G., Tinuper P., Gambardella A., Bianchi A., et al.
HUMAN MOLECULAR GENETICS, vol.21, no.24, pp.5359-5372, 2012 (SCI-Expanded)

LXXV. **The Nuclear Effector of Wnt-Signaling, Tcf1, Functions as a T-Cell-Specific Tumor Suppressor for Development of Lymphomas**
Tiemessen M. M., Baert M. R. M., Schonewille T., Brugman M. H., Famili F., Salvatori D. C. F., Meijerink J. P. P., Ozbek U., Clevers H., van Dongen J. J. M., et al.
PLOS BIOLOGY, vol.10, no.11, 2012 (SCI-Expanded)

LXXVI. **Bromodomain-containing protein 2 gene in photosensitive epilepsy.**
Yavuz E. N., Ozdemir Ö., Catal S., Bebek N., Ozbek U., Baykan B.
Seizure, vol.21, no.8, pp.646-8, 2012 (SCI-Expanded)

LXXVII. **The role of mediastinal adipose tissue 11β-hydroxysteroid d ehydrogenase type 1 and glucocorticoid expression in the development of coronary atherosclerosis in obese patients with ischemic heart disease**
Atalar F., Gormez S., Caynak B., Akan G., Tanriverdi G., Bilgic-Gazioglu S., Gunay D., Duran C., Akpinar B., Ozbek U., et al.
Cardiovascular Diabetology, vol.11, 2012 (SCI-Expanded)

LXXVIII. **Analysis of Chromosomal Aberrations and FLT3 gene Mutations in Childhood Acute Myelogenous Leukemia Patients**
Coskunpinar E., Anak S., Agaoglu L., ÜNÜVAR A., Devecioglu O., Aydogan G., Timur C., Oner A. F., Yildirmak Y., Celkan T., et al.
TURKISH JOURNAL OF HEMATOLOGY, vol.29, no.3, pp.225-232, 2012 (SCI-Expanded)

LXXIX. **Elevated TRIB2 with NOTCH1 activation in paediatric/adult T-ALL**
Hannon M. M., Lohan F., ERBİLGİN Y., SAYİTOĞLU M., O'Hagan K., Mills K., ÖZBEK U., Keeshan K.
BRITISH JOURNAL OF HAEMATOLOGY, vol.158, no.5, pp.626-634, 2012 (SCI-Expanded)

LXXX. **Evaluation of glutathione S-transferase P1 polymorphisms (Ile105Val and Ala114Val) in patients with small cell lung cancer**
Vural B., Yakar F., Derin D., Saip P., Yakar A., Demirkan A., Karabulut A., Ugurel E., Cine N., Kilicaslan Z., et al.
Genetic Testing and Molecular Biomarkers, vol.16, no.7, pp.701-706, 2012 (SCI-Expanded)

LXXXI. **Investigation of Arg399Gln and Arg194Trp Polymorphisms of the XRCC1 (X-Ray Cross-Complementing Group 1) Gene and Its Correlation to Sister Chromatid Exchange Frequency in Patients with Chronic Lymphocytic Leukemia**
Duman N., Aktan M., ÖZTÜRK Ş., PALANDUZ Ş., ÇAKİRİS A., Ustek D., ÖZBEK U., NALÇACI M., ÇEFLE K.
GENETIC TESTING AND MOLECULAR BIOMARKERS, vol.16, no.4, pp.287-291, 2012 (SCI-Expanded)

LXXXII. **SET oncogene is upregulated in pediatric acute lymphoblastic leukemia**
SIRMA EKMEKCİ S., Ekmekci C. G., Kandilci A., GÜLEÇ Ç., Akbiyik M., EMRENCE Z., ABACI N., KARAKAŞ Z., Agaoglu L., ÜNÜVAR A., et al.
TUMORI JOURNAL, vol.98, no.2, pp.252-256, 2012 (SCI-Expanded)

LXXXIII. **Genetic alterations in members of the Wnt pathway in acute leukemia**
Erbilgin Y., Ng Ö., Mavi N., Ozbek U., Sayitoglu M.
Leukemia and Lymphoma, vol.53, no.3, pp.508-510, 2012 (SCI-Expanded)

LXXXIV. **Estimating the Allele Frequency of Autosomal Recessive Disorders through Mutational Records and Consanguinity: The Homozygosity Index (HI)**

Gialluisi A., Pippucci T., Anikster Y., Ozbek U., Medlej-Hashim M., Mégarbané A., Romeo G.
Annals of Human Genetics, vol.76, no.2, pp.159-167, 2012 (SCI-Expanded)

LXXXV. **Genome-wide linkage meta-analysis identifies susceptibility loci at 2q34 and 13q31.3 for genetic generalized epilepsies**
Leu C., de Kovel C. G. F., Zara F., Striano P., Pezzella M., Robbiano A., Bianchi A., Bisulli F., Coppola A., Giallonardo A. T., et al.
EPILEPSIA, vol.53, no.2, pp.308-318, 2012 (SCI-Expanded)

LXXXVI. **Evaluation of PAX5 gene in the early stages of leukemic B cells in the childhood B cell acute lymphoblastic leukemia.**
Firtina S., SAYİTOĞLU M., Hatirnaz O., ERBİLGİN Y., Oztunc C., ÇINAR S., Yildiz I., Celkan T., Anak S., ÜNÜVAR A., et al.
Leukemia research, vol.36, no.1, pp.87-92, 2012 (SCI-Expanded)

LXXXVII. **Anti-neuronal and stress-induced-phosphoprotein 1 antibodies in neuro-Behçet's disease.**
VURAL B., Ugurel E., TÜZÜN E., KÜRTÜNCÜ M., Zuliani L., Cavus F., İÇÖZ S., ERDAĞ E., GÜL A., GÜRE A. O., et al.
Journal of neuroimmunology, vol.239, no.1-2, pp.91-7, 2011 (SCI-Expanded)

LXXXVIII. **Videoendoscopic single-port axillary dissection**
Uras C., ÖZBEK U., Aydogan F.
JOURNAL OF MINIMAL ACCESS SURGERY, vol.7, no.4, pp.246-248, 2011 (SCI-Expanded)

LXXXIX. **Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: Is that true for all the patients?**
Eskazan A. E., Soysal T., ERBİLGİN Y., ÖZBEK U., Ferhanoglu B.
LEUKEMIA RESEARCH, vol.35, no.9, 2011 (SCI-Expanded)

XC. **Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet**
Ostergaard M., Nyvold C. G., Jovanovic J. V., Andersen M. T., Kairisto V., Morgan Y. G., Tobal K., Pallisgaard N., Ozbek U., Pfeifer H., et al.
LEUKEMIA, vol.25, no.7, pp.1168-1173, 2011 (SCI-Expanded)

XCI. **Glutathione S-transferase P1 polymorphisms are associated with time to tumor progression in small cell lung cancer patients**
Saip P., Sen F., Vural B., Ugurel E., Demirkan A., Derin D., Eralp Y., Camlica H., Ustuner Z., ÖZBEK U.
JOURNAL OF BUON, vol.16, no.2, pp.241-246, 2011 (SCI-Expanded)

XCII. **Adipose tissue gene expression of adiponectin, tumor necrosis factor-α and leptin in metabolic syndrome patients with coronary artery disease.**
Gormez S., Demirkan A., ATALAR F., Caynak B., Erdim R., SÖZER V., Gunay D., Akpinar B., Ozbek U., Buyukdevrim A. S.
Internal medicine (Tokyo, Japan), vol.50, no.8, pp.805-10, 2011 (SCI-Expanded)

XCIII. **Association between glutathione s-transferase P1 polymorphisms and time to tumor progression in small cell lung cancer patients.**
Saip P., Sen F., Vural B., Ugurel E., Demirkan A., Derin D., Eralp Y., Camlica H., Ustuner Z., ÖZBEK U.
JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (SCI-Expanded)

XCIV. **Validation of breast cancer nomograms for predicting the non-sentinel lymph node metastases after a positive sentinel lymph node biopsy in a multi-center study**
Gur A. S., Unal B., ÖZBEK U., Ozmen V., Aydogan F., Gokgoz S., Gulluoglu B. M., Aksaz E., Ozbas S., Baskan S., et al.
EJSO, vol.36, no.1, pp.30-35, 2010 (SCI-Expanded)

XCV. **Prognostic significance of NOTCH1 and FBXW7 mutations in pediatric T-ALL**
ERBİLGİN Y., SAYİTOĞLU M., Hatirnaz O., DOĞRU Ö., Akcay A., Tuysuz G., Celkan T., Aydogan G., Salcioglu Z., Timur C., et al.
DISEASE MARKERS, vol.28, no.6, pp.353-360, 2010 (SCI-Expanded)

XCVI. **Comparison of the Cytogenetic and Molecular Analyses in the Assessment of Imatinib Response in Chronic Myelocytic Leukemia**
PALANDUZ Ş., Bayrak A., Sirma S., VURAL B., ÇEFLE K., Ucur A., ÖZTÜRK Ş., YENEREL M. N., BEŞIŞIK S., YAVUZ M. S., et al.

GENETIC TESTING AND MOLECULAR BIOMARKERS, vol.13, no.5, pp.599-602, 2009 (SCI-Expanded)

XCVII. **Effects of Imatinib Mesylate on Renin-Angiotensin System (RAS) Activity During the Clinical Course of Chronic Myeloid Leukaemia**
SAYİTOĞLU M., HAZNEDAROĞLU İ. C., Hatirnaz O., ERBİLGİN Y., AKSU S., Koca E., Adiguzel C., Bayik M., Akalin I., Guelbas Z., et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, vol.37, no.4, pp.1018-1028, 2009 (SCI-Expanded)

XCVIII. **Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study**
Baccarani M., Rosti G., Castagnetti F., Haznedaroglu I., Porkka K., Abruzzese E., Alimena G., Ehrencrona H., Hjorth-Hansen H., Kairisto V., et al.
BLOOD, vol.113, no.19, pp.4497-4504, 2009 (SCI-Expanded)

XCIX. **Seroreactivity against PTEN-induced putative kinase 1 (PINK1) in Turkish patients with Behçet's disease.**
VURAL B., Demirkan A., Ugurel E., Kalaylioglu-Wheeler Z., Esen B. A., Gure A. O., Gül A., Ozbek U.
Clinical and experimental rheumatology, vol.27, no.2 Suppl 53, 2009 (SCI-Expanded)

C. **Prognostic and predictive value of vascular endothelial growth factor and its soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patients**
Ustuner Z., Saip P., Yasasever V., Vural B., Yazar A., BAL C., Ozturk B., ÖZBEK U., Topuz E.
MEDICAL ONCOLOGY, vol.25, no.4, pp.394-399, 2008 (SCI-Expanded)

CI. **Presence of fatty-acid-binding protein 4 expression in human epicardial adipose tissue in metabolic syndrome**
VURAL B., ATALAR F., Ciftci C., Demirkan A., Susleyici-Duman B., Gunay D., Akpinar B., Sagbas E., ÖZBEK U., Buyukdevrim A. S.
CARDIOVASCULAR PATHOLOGY, vol.17, no.6, pp.392-398, 2008 (SCI-Expanded)

CII. **Definition of C282Y mutation in a hereditary hemochromatosis family from Turkey**
Yoenal O., Hatirnaz Ö., Akyuez F., Koroglu G., Ozbeik U., Cefle K., Mungan Z.
Turkish Journal of Gastroenterology, vol.18, no.1, pp.53-57, 2007 (SCI-Expanded)

CIII. **HFE gene mutation, chronic liver disease, and iron overload in Turkey**
Yoenal O., Hatirnaz Ö., Akyuez F., Oezbek U., Demir K., Kaymakoglu S., Oekten A., Mungan Z.
Digestive Diseases and Sciences, vol.52, no.11, pp.3298-3302, 2007 (SCI-Expanded)

CIV. **Angiotensinogen M235T polymorphism and left ventricular indices in treated hypertensive patients with normal coronary arteries**
Olkay A., Nişansi Y., Ekmekçi C. G., Özbek U., Sezer M., Umman B., Buğra Z.
Anadolu Kardiyoloji Dergisi, vol.7, no.3, pp.257-261, 2007 (SCI-Expanded)

CV. **The SOCS-1 gene methylation in chronic myeloid leukemia patients**
Hatirnaz M., Ure U., Ar C., Akyerli C., Soysal T., Ferhanoglu B., Oezcelik T., Ozbek U.
American Journal of Hematology, vol.82, no.8, pp.729-730, 2007 (SCI-Expanded)

CVI. **Autologous stem cells collected after debulking by high dose chemotherapy in late phase chronic myeloid leukemia may improve Imatinib efficacy**
BEŞIŞIK S., Ozturk G. B., Caliskan Y., Nalcaci M., Gurses N., Cin N., ÖZBEK U., Sargin D.
TRANSFUSION AND APHERESIS SCIENCE, vol.36, no.1, pp.91-94, 2007 (SCI-Expanded)

CVII. **SET-CAN, the product of the t(9;9) in acute undifferentiated leukemia, causes expansion of early hematopoietic progenitors and hyperproliferation of stomach mucosa in transgenic mice**
Özbek U., Kandilci A., Van Baal S., Bonten J., Boyd K., Franken P., Fodde R., Grosveld G. C.
American Journal of Pathology, vol.171, no.2, pp.654-666, 2007 (SCI-Expanded)

CVIII. **Association between reduced levels of MEFV messenger RNA in peripheral blood leukocytes and acute inflammation**
Üstek D., Ekmekci C. G., Selçukbiricik F., ÇAKİRİS A., Oku B., VURAL B., Yanar H., Taviloglu K., Özbek U., Gül A.
Arthritis and Rheumatism, vol.56, no.1, pp.345-350, 2007 (SCI-Expanded)

CIX. **Negative association of endothelial nitric oxide gene polymorphism with hypertension in Turkish patients: Effect of ecNOS polymorphism on left ventricular hypertrophy**

Olcay A., Ekmekci C. G., Ozbek U., Sezer M., Barcin C., Arslan E., Boztosun B., Nisanci Y.
Cardiovascular Ultrasound, vol.4, 2006 (SCI-Expanded)

CX. **Aldosterone synthase -344c/t and angiotensin-converting enzyme I/D polymorphisms in Turkish hypertensive patients with normal coronary arteries**
Olcay A., Nisanci Y., Ekmekci C. G., Umman B., Bugra Z., Sezer M., Acar R. D., Ozbek U.
Acta Cardiologica, vol.61, no.1, pp.29-34, 2006 (SCI-Expanded)

CXI. **Polymorphism of endothelial nitric oxide synthase gene in patients with erectile dysfunction**
Erkan E., Muslumanoglu A. Y., Oktar T., Sanli O., Ozbek U., Kadioglu A.
Journal of Sexual Medicine, vol.3, no.1, pp.69-76, 2006 (SCI-Expanded)

CXII. **Invited comments on Erkan et al. Polymorphism of endothelial nitric oxide synthase gene in patients with erectile dysfunction - Response**
Erkan E., Muslumanoglu A., OKTAR T. M., Sanli O., ÖZBEK U., KADIOĞLU A.
JOURNAL OF SEXUAL MEDICINE, vol.3, no.1, pp.76, 2006 (SCI-Expanded)

CXIII. **Differing DNA methylation patterns and gene mutation frequencies in colorectal carcinomas from Middle Eastern countries**
Chan A. O., Soliman A. S., Zhang Q., Rashid A., Bedeir A., Houlihan P. S., Mokhtar N., Al-Masri N., Ozbek U., Yaghan R., et al.
Clinical Cancer Research, vol.11, no.23, pp.8281-8287, 2005 (SCI-Expanded)

CXIV. **Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer**
Einav U., Tabach Y., Getz G., Yitzhaky A., Ozbek U., Amariglio N., Izraeli S., Rechavi G., Domany E.
Oncogene, vol.24, no.42, pp.6367-6375, 2005 (SCI-Expanded)

CXV. **Frequency of SOX group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters**
VURAL B., Chen L., Saip P., Chen Y., Ustuner Z., Gonen M., Simpson A. J. G., Old L. J., Ozbek U., Gure A. O.
Cancer, vol.103, no.12, pp.2575-2583, 2005 (SCI-Expanded)

CXVI. **The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis**
Cardone M., Kandilci A., Carella C., Nilsson J., Brennan J., Sirma S., Ozbek U., Boyd K., Cleveland J., Grosveld G.
MOLECULAR AND CELLULAR BIOLOGY, vol.25, no.6, pp.2395-2405, 2005 (SCI-Expanded)

CXVII. **Expression of IFITM1 in chronic myeloid leukemia patients**
AKYERLİ BOYLU C., BEKSAÇ M., Holko M., Frevel M., Dalva K., ÖZBEK U., Soydan E., Ozcan M., Ozet G., Ilhan O., et al.
Leukemia Research, vol.29, no.3, pp.283-286, 2005 (SCI-Expanded)

CXVIII. **Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia**
Ekmekci C. G., Gutiérrez M. I., Siraj A. K., Ozbek U., Bhatia K.
American Journal of Hematology, vol.77, no.3, pp.233-240, 2004 (SCI-Expanded)

CXIX. **NAD(P)H:quinone oxidoreductase 1 null genotype is not associated with pediatric de novo acute leukemia**
Sirma S., Agaoglu L., Yildiz I., Cayli D., Horgusluoglu E., Anak S., Yuksel L., Unuvar A., Celkan T., Apak H., et al.
Pediatric Blood and Cancer, vol.43, no.5, pp.568-570, 2004 (SCI-Expanded)

CXX. **Quantification of the FLI1 and CXCR4 gene expressions in acute lymphoblastic leukemia (ALL) patients with t(12,21)**
SAVLI H., Hatirnaz Ö., Sirma S., Özdemir S., Özbek U.
Turkish Journal of Haematology, vol.21, no.2, pp.87-92, 2004 (SCI-Expanded)

CXXI. **Real-Time PCR analysis of af4 and dek genes expression in acute promyelocytic leukemia t(15;17) patients**
Savli H., Sirma S., Nagy B., Aktan M., Dincol G., Salcioglu Z., SARPER N., ÖZBEK U.
EXPERIMENTAL AND MOLECULAR MEDICINE, vol.36, no.3, pp.279-282, 2004 (SCI-Expanded)

CXXII. **Expression Analysis of DEK, AF4 and FLI1 Genes in All-Trans-Retinoic Acid (ATRA) Treated Acute Promyelocytic Leukaemia t(15;17) Patients by Quantitative Real-Time PCR**
SAVLI H., Sirma S., Nagy B., Aktan M., Dinçol G., Salcioğlu Z., Özbek U.
Turkish Journal of Medical Sciences, vol.34, no.2, pp.85-89, 2004 (SCI-Expanded)

CXXIII. **Methylenetetrahydrofolate reductase C677T polymorphism and toxicity in allogeneic hematopoietic cell transplantation [5]**
Kalayoglu-Besisik S., Caliskan Y., Sargin D., Gurses N., Ozbek U.
Transplantation, vol.76, no.12, pp.1775-1777, 2003 (SCI-Expanded)

CXXIV. **Real-time PCR analysis of the apoptosis related genes in ATRA treated APL t(15;17) patients**
Savli H., Sirma S., Nagy B., Aktan M., Dincol G., ÖZBEK U.
EXPERIMENTAL AND MOLECULAR MEDICINE, vol.35, no.5, pp.454-459, 2003 (SCI-Expanded)

CXXV. **Analysis of MYH Tyr165Cys and Gly382Asp variants in childhood leukemias**
Akyerli C., Ozbek U., Aydin-Sayitoglu M., Sirma S., Ozcelik T.
Journal of Cancer Research and Clinical Oncology, vol.129, no.10, pp.604-605, 2003 (SCI-Expanded)

CXXVI. **Concurrent methylation of multiple genes in childhood ALL: Correlation with phenotype and molecular subgroup**
Gutierrez M., Siraj A., Bhargava M., Ozbek U., Banavali S., Chaudhary M., El Sohl H., Bhatia K.
Leukemia, vol.17, no.9, pp.1845-1850, 2003 (SCI-Expanded)

CXXVII. **Tumour necrosis factor-alpha gene promoter region -308 and -376 G-->A polymorphisms in Behçet's disease.**
Duymaz-Tozkir J., Gül A., Uyar F. A., Ozbek U., Saruhan-Direskeneli G.
Clinical and experimental rheumatology, vol.21, no.4 Suppl 30, 2003 (SCI-Expanded)

CXXVIII. **Expression stability of six housekeeping genes: a proposal for resistance gene quantification studies of Pseudomonas aeruginosa by real-time quantitative RT-PCR**
Savli H., Karadenizli A., KOLAYLI F., Gundes S., ÖZBEK U., Vahaboglu H.
JOURNAL OF MEDICAL MICROBIOLOGY, vol.52, no.5, pp.403-408, 2003 (SCI-Expanded)

CXXIX. **Prognostic significance of the TEL-AML1 fusion gene in pediatric acute lymphoblastic leukemia in Turkey**
ÖZBEK U., Sirma S., Agaoglu L., Yuksel L., Anak S., Yildiz I., Devecioglu O., Timur C., Meral A., Gedikoglu G.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, vol.25, no.3, pp.204-208, 2003 (SCI-Expanded)

CXXX. **Quantification of the FLI1 gene expression by real-time quantitative RT-PCR**
SAVLI H., Sirma S., Özbek U.
Turkish Journal of Medical Sciences, vol.33, no.1, pp.21-25, 2003 (SCI-Expanded)

CXXXI. **Preclinical validation of a monochrome real-time multiplex assay for translocations in childhood acute lymphoblastic leukemia**
Siraj A. K., Ozbek U., Sazawal S., Sirma S., Timson G., Al-Nasser A., Bhargava M., El Solh H., Bhatia K., Gutiérrez M. I.
Clinical Cancer Research, vol.8, no.12, pp.3832-3840, 2002 (SCI-Expanded)

CXXXII. **Activated protein C resistance in polycythemia vera**
Günay A., Öztürk A., Budak T., Özbek U., Üskent N.
Turkish Journal of Haematology, vol.18, no.3, pp.157-164, 2001 (SCI-Expanded)

CXXXIII. **Detection of BCR/ABL transcripts by reverse transcriptase polimerase chain reaction in pediatric acute lymphoblastic leukemia: Incidence and clinical features**
Sarper N., Özbek U., Ağaoğlu L., Özgen Ü., Kandilci A., Sirma S., Anak S., Yalman N., Eryilmaz E., Devecioğlu Ö., et al.
Turkish Journal of Haematology, vol.17, no.4, pp.197-206, 2000 (SCI-Expanded)

CXXXIV. **Is AML1/ETO gene expression a good prognostic factor in pediatric acute myeloblastic leukemia?**
SARPER N., ÖZBEK U., Agaoglu L., Ozgen U., Eryilmaz E., YALMAN N., Anak S., Devecioglu O., Gedikoglu G.
PEDIATRIC HEMATOLOGY AND ONCOLOGY, vol.17, no.7, pp.577-583, 2000 (SCI-Expanded)

CXXXV. **wt1 gene expression in childhood acute leukemias**
Ozgen U., Anak S., ÖZBEK U., SARPER N., Eryilmaz E., Agaoglu L., Devecioglu O., Yalman N., Gedikoglu G.
ACTA HAEMATOLOGICA, vol.103, no.4, pp.229-230, 2000 (SCI-Expanded)

CXXXVI. **Prevalence of factor V Leiden in patients with retinal vein occlusion.**
Demirci F. Y., Güney D. B., Akarçay K., Kir N., Ozbek U., Sirma S., Unaltuna N., Ongör E.
Acta ophthalmologica Scandinavica, vol.77, no.6, pp.631-3, 1999 (SCI-Expanded)

CXXXVII. **Frequency of factor V leiden (Arg506Gln) in Turkey [2]**
Ozbek U., Tangun Y.

British Journal of Haematology, vol.97, no.2, pp.504-505, 1997 (SCI-Expanded)

CXXXVIII. **Frequency of factor V Leiden in Turkey [1]**
Ozbek U., Tangun Y.
International Journal of Hematology, vol.64, pp.291-292, 1996 (SCI-Expanded)

CXXXIX. **Monosomy 7 myeloproliferative disease associated with neurofibromatosis type I: A case report**
Savasan S., Zulfikar B., Ozgeneci A., ÖZBEK U., Sengun Z.
JOURNAL OF CHEMOTHERAPY, vol.8, no.3, pp.243-246, 1996 (SCI-Expanded)

Articles Published in Other Journals

I. **Macro-Capsule Fabrication via 3D Printing for Mesenchymal Stem Cell Encapsulation**
karaca m. a., DİLEK KANÇAĞI D., ÖZBEK U., OVALI E., GÖK Ö.
International journal of advances in engineering and pure sciences (Online), 2023 (Peer-Reviewed Journal)

II. **Aberrant Methylation Profile and Microsatellit Instability in Turkish Sporadic Colorectal Carcinoma**
Ekmekci C. G., Gulluoglu M., Kapran Y., Dizdaroglu F., ÖZBEK U.
BEZMIALEM SCIENCE, vol.7, no.2, pp.86-94, 2019 (Peer-Reviewed Journal)

III. **Cerebral Palsy and Genetics**
Akcakaya N. H., Yapici Z., ÖZBEK U.
TURKISH JOURNAL OF NEUROLOGY, vol.24, no.1, pp.1-2, 2018 (Peer-Reviewed Journal)

IV. **Hematolojik Maligniteler Moleküler Genetik Etiyoloji ve 2016 Dünya Sağlık Örgütü Sınıflaması**
HATIRNAZ NG Ö., ÖZBEK U.
Türkiye Klinikleri Dergisi Tıbbi Genetik Özel Sayısı, vol.2, no.2, pp.88-98, 2017 (Peer-Reviewed Journal)

V. **Does 8q24 region have potenttial risk for childhood acute lymphoblatic leukemia**
HATIRNAZ NG Ö., Can İ., Fırtına S., ERBİLGİN Y., ÖZBEK U., SAYİTOĞLU M.
DETAE, 2015 (Peer-Reviewed Journal)

VI. **First Steps of the Genetic Monitorization in Primary Immune Deficiencies in the Lead of Prof. Dr. Işil Barlan in Turkey**
Ng Y. Y., Şişko S., Hatırnaz Ng Ö., Çatal Tatonyan S., Sever Kaya D., Fırtına S., Sayitoğlu M., Özbek U.
Turkish Journal of Immunology, vol.3, no.2, pp.47, 2015 (Scopus)

VII. **First Steps of the Genetic Monitorization in Primary Immune Deficiencies in the Lead of Prof. Dr. Isil Barlan in Turkey**
Ng Y. Y., Sisko S., HATIRNAZ NG Ö., Tatonyan S. C., ŞATANA D., FIRTINA S., SAYİTOĞLU M., ÖZBEK U.
TURKISH JOURNAL OF IMMUNOLOGY, no.2, pp.47, 2015 (ESCI)

VIII. **8q24 bölgesi çocukluk çağı lenfoblastik lösemiler için potansiyel risk oluşturur mu**
HATIRNAZ NG Ö., Can İ., SİNEM F., ERBİLGİN Y., ÖZBEK U., SAYİTOĞLU M.
Deneysel Tıp Dergisi, vol.5, no.9, 2015 (Peer-Reviewed Journal)

IX. **Association of MDR1 gene polymorphism in patients with temporal lobe epilepsy Temporal lob epilepsili hastalarda MDR1 gen polimorfizmi ile ilişki**
ÇİNE N., Sargin G., BEBEK N., Gürses C., Baykan B., Özbek U., Gökyiğit A.
Journal of Neurological Sciences, vol.30, no.1, pp.4-11, 2013 (Scopus)

X. **AKUT LÖSEMİ HÜCRE SERİLERİNDE BETA KATENİN siRNA UYGULAMALARI**
HATIRNAZ NG Ö., ERBİLGİN Y., AKTAŞ E., DENİZ G., ÖZBEK U., SAYİTOĞLU M.
DENEYSEL TIP DERGİSİ, vol.2, no.3, pp.16-22, 2012 (Peer-Reviewed Journal)

XI. **BETA KATENİN VE AXIN2 PROTEİNLERİ ETKİLEŞİMLERİNİN PROKSİMİTİ LİGASYON ASSAY YAKINSAL BAĞLANMA TESPİTİ ILE GÖRÜNTÜLENMESİ**
ERBİLGİN Y., HATIRNAZ NG Ö., SAYİTOĞLU M., SÖDERBERG O., ÖZBEK U.
DENEYSEL TIP DERGİSİ, vol.1, no.2, pp.24-27, 2011 (Peer-Reviewed Journal)

XII. **Cloning of chimerical translocations as positive control for molecular genetic diagnosis of leukemia.**
Ustek D., Sırma S., Cakiris A., Coşan F., Oku B., Özbek U.
Turkish journal of haematology : official journal of Turkish Society of Haematology, vol.25, no.1, pp.20-3, 2008

(Scopus)

XIII. **CYP1A1, GSTM1 and NQO1 gene polymorphisms: Genetic risk factors for small cell lung cancer**
Demirkan A., VURAL B., Üstüner Z., Uygun K., Açikalin B. Ö., Derin D., Saip P., Özbek U.
Turkish Journal of Cancer, vol.35, no.4, pp.171-176, 2005 (Scopus)

XIV. **Quantification of All-Trans-Retinoic Acid (ATRA) Dependent Expression of CXCR4 Gene in Acute Promyelocytic Leukaemia.**
Savlı H., Sırma S., Aktan M., Dınçol G., Özbek U.
Turkish journal of haematology : official journal of Turkish Society of Haematology, vol.20, no.3, pp.153-9, 2003 (Scopus)

XV. **Prognostic significance of wilms tumor 1 gene in childhood acute Lymphoblastic Leukemia.**
Özgen Ü., Anak S., Özbek U., Sarper N., Eryılmaz E., Ağaoğlu L., Devecioğlu Ö., Yalman N., Gedikoğlu G.
Turkish journal of haematology : official journal of Turkish Society of Haematology, vol.17, no.4, pp.183-8, 2000 (Scopus)

XVI. **Detection of BCR/ABL transcripts by reverse transcriptase polimerase chain reaction in pediatric acute Lymphoblastic Leukemia: ıncidence and clinical eatures.**
Sarper N., Özbek U., Ağaoğlu L., Özgen Ü., Kandilci A., Sırma S., Anak S., Yalman N., Eryılmaz E., Devecioğlu Ö., et al.
Turkish journal of haematology : official journal of Turkish Society of Haematology, vol.17, no.4, pp.197-206, 2000 (Scopus)

XVII. **Coagulation factor V gene mutation increases the risk of venous thrombosis in behçet's disease.**
Gül A., Ozbek U., Oztürk C., Inanç M., Koniçe M., Ozçelik T.
British journal of rheumatology, vol.35, no.11, pp.1178-80, 1996 (Peer-Reviewed Journal)

Books & Book Chapters

I. **Biyobankalar**
Erbilgin Y., Uğur İşeri S. A., Özbek U.
in: Tıp Bilişimi, Nilgün Bozbuğa,Sevinç Gülseçen, Editor, Istanbul University, İstanbul, pp.159-169, 2021

II. **Cerebral Palsy ve Genetik**
Özbek U. (Editor)
Boyut Yayın Grubu, İstanbul, 2019

III. **Basic Concepts in Genetics**
Erbilgin Y., Özbek U.
in: Cerebral Palsy and Genetics, Hande Akçakaya,Uğur Özbek, Editor, Boyut Yayın Grubu, İstanbul, pp.11-26, 2019

Refereed Congress / Symposium Publications in Proceedings

I. **Primer İmmün Yetmezliklerde Rutin Tanı Deneyimi: 2010-2016 Yılları Aziz Sancar Deneysel Tıp Araştırma Enstitüsü, Genetik Anabilim Dalı Verileri**
HATIRNAZ NG Ö., NG Y. Y., Şişko S., Çatal Tatonyan S., Firtina S., Sever Kaya D., ÖZBEK U., SAYİTOĞLU M.
3.Klinik İmmünoloji Kongresi, Turkey, 12 April 2017 - 15 April 3017

II. **DESIGN OF CELL MICROCAPSULES FOR CELLULAR THERAPY**
karaca m. a., DİLEK KANÇAĞI D., ÖZBEK U., OVALI E., GÖK Ö.
8th International FAPS Polymer Congress, 12 - 14 September 2023

III. **From patient to function: modeling CRIM1 in xenopus tropicalis**
AKGÜN DOĞAN Ö., Viviano S., HATIRNAZ NG Ö., Agaoglu N. B., Ji W., Jeffries L., Ozbek U., Lakhani S., Khokha M., Deniz E., et al.
55th European-Society-of-Human-Genetics (ESHG) Conference, Vienna, Austria, 11 - 14 June 2022, pp.656-657

IV. **Molecular Diagnosis of TYR Negative Albinism Patients by Clinical Exome Sequencing**
Akyoney S., Sahin I., Unal B., Agaoglu N. B., Mudun A., Parlakgunes Z., Yilmaz E., ALANAY Y., ÖZBEK U., HATIRNAZ

NG Ö.
54th Conference of the European-Society-of-Human-Genetics (ESHG), ELECTR NETWORK, 28 - 31 August 2021, pp.118

V. **KALITSAL KANSERLERDE KLİNİK ÖNEMİ BİLİNMEYEN GENOMİK VARYANTLARIN FONKSİYONEL KARAKTERİZASYONU VE SINIFLANDIRILMASI**
Üstün Yılmaz S., Özdemir Ö., AĞAOĞLU N. B., HATIRNAZ NG Ö., MÜFTÜOĞLU M., ÖZBEK U.
8.TÜRK TIBBİ ONKOLOJİ KONGRESİ, Antalya, Turkey, 3 - 07 November 2021

VI. **Biallelic NALCN variant detected by homozygosity mapping and whole exome sequencing in a consanguineous family from Turkey**
Süsgün S., Yücesan E., Çalık M., Özbek U., Uğur İşeri S. A.
European Society of Human Genetics Annual Meeting 2020, Berlin, Germany, 6 - 09 June 2020, pp.1

VII. **Screening TYR gene variations in Turkish oculocutaneuse albinism patients**
Ng O. H., YILMAZ E., Parlakgunes Z., YARARBAŞ K., Ziylan S., ALANAY Y., ÖZBEK U.
52nd Conference of the European-Society-of-Human-Genetics (ESHG), Gothenburg, Sweden, 15 - 18 June 2019, vol.27, pp.1233-1234

VIII. **IKZF1 Deletions at Diagnose and Relapse of Childhood B-ALL**
Erbilgin Y., Firtina S., Ng O. H., Celkan T., Karakas Z., Anak S. S., Sarper N., Zengin E., Eskazan A., Sayitoglu M., et al.
59th Annual Meeting of the American-Society-of-Hematology (ASH), Georgia, United States Of America, 9 - 12 December 2017, vol.130

IX. **Çocukluk Çağı B-All Hastalarında Tanı Ve Nüks Anındaki Moleküler Değişimlerin Dinamiği**
FIRTINA S., ERBİLGİN Y., TAŞAR O., MERCAN S., HATIRNAZ N. Ö., şişko s., KÜÇÜKCANKURT F., CELKAN T. T., KARAKAŞ Z., TUĞCU D., et al.
43. Ulusal hematoloji kongresi, Turkey, 1 - 04 November 2017

X. **Çocukluk Çağı B-ALL Hastalarinda IKZF1 Delesyonlarinin Araştırılması**
ERBİLGİN Y., HATIRNAZ NG Ö., SAYİTOĞLU M., ÖZBEK U.
43. Ulusal Hematoloji Kongresi, Turkey, 1 - 04 November 2017

XI. **SKF82958'xxİN SIÇANLARDA NALOKSON İLE BAŞLATILAN MORFİN YOKSUNLUK SENDROMU BELİRTİLERİ VE HİPOKAMPAL DOKU PLAZMİNOJEN AKTİVATÖRÜ mRNA DÜZEYLERİ ÜZERİNE ETKİLERİ**
Aslan A., HATIRNAZ NG Ö., Taşar O., ÖZBEK U., YAMANTÜRK ÇELİK A. P.
24. Ulusal Farmakolji kongresi, Turkey, 17 - 22 October 2017

XII. **Effects of enriched environment and memantine on naloxone precipitated morphine-abstinence syndrome in rats**
ASLAN A., HATIRNAZ NG Ö., TAŞAR O., ÖZBEK U., YAMANTÜRK ÇELİK A. P.
6th Meeting of the International Drug Abuse Research Society, Dubrovnik, Croatia, 4 - 08 September 2017

XIII. **Research Biobank for Leukemia**
ERBİLGİN Y., HATIRNAZ NG Ö., Fırtına S., Khodzaev K., ÖZBEK U., SAYİTOĞLU M., UĞUR İŞERİ S. A.
Towards Harmonyin Biobanking, Switzerland, 01 June 2017 - 03 June 2107

XIV. **PTEN AND AKT1 GENE VARIATIONS IN CHILDHOODT-ALL PATIENTS**
Küçükcankurt F., HATIRNAZ NG Ö., ERBİLGİN Y., ÖZBEK U., KARAKAŞ Z., CELKAN T. T., SAYİTOĞLU M.
6th International Congress onLeukemia – Lymphoma – Myeloma, 11 - 13 May 2017

XV. **Turkish National Severe Congenital Neutropenia Registry**
YILMAZ KARAPINAR D., KARAKAŞ Z., PATIROĞLU T., Metin A., Caliskan U., CELKAN T. T., YILMAZ B., Karapinar T. H., Karaman S., Akinci B., et al.
58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), California, United States Of America, 3 - 06 December 2016, vol.128

XVI. **Primer İmmün Yetersizliklerde Hastalıkla İlişkili Aday Varyantların Tespiti**
Fırtına S., NG Y. Y., HATIRNAZ NG Ö., CAMCIOĞLU Y., AYDINER E., Kaya A., Çipe F., ÖZBEK U., SAYİTOĞLU M.
12.Ulusal Tıbbi Genetik kongresi, Turkey, 5 - 09 October 2016

XVII. **GLUT1 Yetmezlik Sendromu ile İlişkili SLC2A1 De Novo Gen Varyantlarının Tespiti**
YÜCESAN E., KARA B., Özdemir Ö., KARACAN İ., UĞUR İŞERİ S. A., ÖZBEK U.

10. Ulusal Epilepsi Kongrei, Turkey, 12 - 15 May 2016

XVIII. **Prognostic Significance of IKZF1 Deletions in Childhood B ALL**
ERBİLGİN Y., Fırtına S., HATIRNAZ NG Ö., KARAKAŞ Z., CELKAN T. T., SARPER N., Aydoğan G., Khodzhaev K., SAYİTOĞLU M., ÖZBEK U.
27th Annual Meeting of the International BFM Study Group, 23 - 26 April 2016

XIX. **Pathways associated with relapse and high risk in childhood acute lymphoblastic leukemia**
ERBİLGİN Y., HATIRNAZ NG Ö., İşlek B., Fırtına S., CELKAN T. T., ANAK S. S., KARAKAŞ Z., SARPER N., ZENGİN E., Türkkan E., et al.
Europian Human Genetics Conference 2015, 6 - 09 June 2015

XX. **77 new CNV regions identified in ITP provide evidence for genetic predisposition**
AR M. C., Yücesan E., YALNIZ F. F., HATIRNAZ NG Ö., Salihoğlu A., BERK S., Eskazan A. E., ÖNGÖREN AYDIN Ş., BAŞLAR Z., ÖZBEK U., et al.
57th Annual Meeting & Exposition, 5 - 08 December 2015

XXI. **Down regulation of SnoN SKIL gene in T cel acute lymphoblastic leukemia**
HATIRNAZ NG Ö., Taşar O., NG Y. Y., Öztunç C., ERBİLGİN Y., SAYİTOĞLU M., ÖZBEK U.
Europian Human GeneticsConference 2015, 6 - 09 June 2015

XXII. **hRgr overexpretion in human T cell malignancy**
Burak İ., KARAKAŞ Z., SOYSAL T., SAYİTOĞLU M., Süzme R., ÖZBEK U.
Europian Human GeneticsConference 2015, 6 - 09 June 2015

XXIII. **New CNV Regions Identified in ITP Provide Evidence for Genetic Predisposition**
AR M. C., YÜCESAN E., Yalniz F., HATIRNAZ NG Ö., SALİHOĞLU A., Berk S., EŞKAZAN A. E., Ongoren S., Baslar Z., ÖZBEK U., et al.
57th Annual Meeting of the American-Society-of-Hematology, Florida, United States Of America, 5 - 08 December 2015

XXIV. **Imatinib Mesylate Reduces Bone Marrow Fibrosis and Overwhelms the Adverse Prognostic Impact of Reticulin Formation in Patients with Chronic Myeloid Leukemia**
Simsek E. T., EŞKAZAN A. E., Cengiz M., AR M. C., Ekizoglu S., SALİHOĞLU A., Gulturk E., ELVERDİ T., Aydin S. O., DEMİRÖZ A. S., et al.
57th Annual Meeting of the American-Society-of-Hematology, Florida, United States Of America, 5 - 08 December 2015

XXV. **Pediatrik T ALL hastalarında regulatör mikroRNA ların yolak analizleri ile belirlenmesi**
Khodzhaev K., HATIRNAZ NG Ö., ERBİLGİN Y., ÖZBEK U., SAYİTOĞLU M.
14. Tıbbi Biyoloji ve Genetik Kongresi, Turkey, 27 - 30 October 2015

XXVI. **T Hücreli Akut Lenfoblastik Lösemi Hücre Hatlarında SKIL geni ve hsa miR 223 Fonksiyonel İlişkisi**
HATIRNAZ NG Ö., ORÇUN T., NG Y. Y., CEREN Ö., ÖZBEK U., SAYİTOĞLU M.
41. ULUSAL HEMATOLOJİ KONGRESİ, Turkey, 21 - 24 October 2015

XXVII. **KML monitorizasyonunda yeni bir kantitatif analiz raporlama ve takip yazılımı REPTILE**
HATIRNAZ NG Ö., ÖZDEMİR Ö., SAYİTOĞLU M., ÖZBEK U.
41. ULUSAL HEMATOLOJİ KONGRESİ, Turkey, 21 - 24 October 2015

XXVIII. **Akraba Evliliği Yapmış Geniş Bir Ailede Birbirinden Bağımsız Olarak Gözlenen Unverricht-Lundborg Hastalığı ve Motor Mental Gelişme Geriliğinin Genetik Olarak İncelenmesi**
YÜCESAN E., TUNCER KILINÇ F. N., ÇALIK M., BEBEK N., ÖZBEK U., UĞUR İŞERİ S. A.
2. Ulusal Çocuk Genetik Sempozyumu, Turkey, 22 - 24 October 2015

XXIX. **GENERIC IMATINIB IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) PATIENTS IN CHRONIC PHASE: UPDATED DATA FROM A TURKISH CML COHORT**
EŞKAZAN A. E., Ayer M., Kantarcioglu B., Demirel N., Aydin D., Aydinli F., Yokus O., Sadri S., Erdogan I., BERK S., et al.
20th Congress of European-Hematology-Association, Vienna, Austria, 11 - 14 June 2015, pp.447-448

XXX. **OUTCOMES OF CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WITH 10%<= AND > 10% BCR-ABL1 (IS) TRANSCRIPT LEVELS AFTER 3 MONTHS OF GENERIC IMATINIB TREATMENT**
Baslar Z., EŞKAZAN A. E., Ayer M., Kantarcioglu B., Demirel N., Aydin D., Aydinli F., Yokus O., Sadri S., Erdogan I., et al.

20th Congress of European-Hematology-Association, Vienna, Austria, 11 - 14 June 2015, pp.439-440

XXXI. **NILOTINIB RESULTS IN IMPROVED RATES OF MOLECULAR RESPONSE IN TURKISH NEWLY DIAGNOSED CML-CP PATIENTS: A 24-MONTH UPDATE**
SAYDAM G., HAZNEDAROĞLU İ. C., Kaynar L., Yavuz A. S., YILDIZ A. R., Guvenc B., Akay O. M., Baslar Z., ÖZBEK U., SÖNMEZ M., et al.
20th Congress of European-Hematology-Association, Vienna, Austria, 11 - 14 June 2015, vol.100, pp.695-696

XXXII. **THE EFFICACY AND SAFETY OF GENERIC IMATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) AFTER SWITCHING FROM GLIVEC: UPDATED DATA FROM CERRAHPASA CML COHORT**
Soysal T., EŞKAZAN A. E., Sadri S., Erdogan I., BERK S., Yalniz F. F., ELVERDİ T., SALİHOĞLU A., AR M. C., AYDIN S., et al.
20th Congress of European-Hematology-Association, Vienna, Austria, 11 - 14 June 2015, pp.447

XXXIII. **THIRD-LINE TREATMENT WITH 2ND GENERATION TYROSINE KINASE INHIBITORS (TKIS) IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WHO FAILED TWO PRIOR TKIS: A SINGLE CENTER EXPERIENCE OF 21 PATIENTS**
SALİHOĞLU A., EŞKAZAN A. E., Suzan V., Savci S., Erdogan I., BERK S., Yalniz F. F., ELVERDİ T., AR M. C., AYDIN S., et al.
20th Congress of European-Hematology-Association, Vienna, Austria, 11 - 14 June 2015, pp.696-697

XXXIV. **INTERNATIONAL CONTROL ROUND FOR DEEP SEQUENCING ANALYSIS OF BCR-ABL KINASE DOMAIN MUTATIONS IN 11 LABORATORIES FROM 7 EUROPEAN COUNTRIES**
Ernst T., Rinke J., Stiens M., Soverini S., De Benedittis C., Polakova K. M., Polivkova V., Schnittger S., Baer C., Mueller M., et al.
20th Congress of European-Hematology-Association, Vienna, Austria, 11 - 14 June 2015, pp.326

XXXV. **PEDIATRIC TEL-AML1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS SHOW INCREASED MN1 EXPRESSION**
YENER M. D., Numata M., SIRMA EKMEKCİ S., AYDIN M., Grosveld G., ÖZBEK U., GÜLEÇ Ç., Anak S., KARAMAN S., Ozturk G., et al.
20th Congress of European-Hematology-Association, Vienna, Austria, 11 - 14 June 2015, pp.633

XXXVI. **Down regulation of SnoN SKIL gene in T cell acute lymphoblastic leukemia**
HATIRNAZ NG Ö., Taşar O., NG Y. Y., CEREN Ö., ERBİLGİN Y., SAYİTOĞLU M., ÖZBEK U.
5th International Congress of Leukemia Lymphoma Myeloma, 21 - 23 May 2015

XXXVII. **14 Yıllık Huntington Hastalığı Genetik Tanı Sonuçlarının Değerlendirilmesi**
KÖMÜRCÜ BAYRAK E., PODA M., GÜVEN Z. G., GEYİK F., ÇOBAN N., GÜLEÇ Ç., ABACI N., AKBAŞ F., ÖZBEK U., ÜNALTUNA N.
6. DETAE Günleri, Turkey, 24 November 2014

XXXVIII. **Correlation between phenotypic and genotypic tetracycline resistance of Escherichia coli isolates from food of animal origin**
MURATOĞLU K., Ozdemir O., YILMAZ EKER F., Bayrakal M., Levent G., UĞUR İŞERİ S. A., ÖZBEK U., Ciftcioglu G.
European Biotechnology Congress, Lecce, Italy, 15 - 18 May 2014

XXXIX. **Molecular analysis of consanguineous rare syndromes in Turkey**
ÖZBEK U.
European Biotechnology Congress, Lecce, Italy, 15 - 18 May 2014

XL. **FIRST LINE TREATMENT OF CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WITH THE GENERIC FORMULATIONS OF IMATINIB MESYLATE**
EŞKAZAN A. E., Baslar Z., Ayer M., Kantarcioglu B., Arica D., Demirel N., Aydin D., Yalniz F. F., ELVERDİ T., SALİHOĞLU A., et al.
19th Congress of the European-Hematology-Association, Milan, Italy, 12 - 15 June 2014, pp.330-331

XLI. **TWONOVEL AND THREE KNOWN EPM2A AND NHLRC1 (EPM2B) GENE VARIANTS LEADING TO LAFORA DISEASE IN TURKISH PATIENTS**
BEBEK N., ÖZDEMİR O., Ore O. E., UĞUR İŞERİ S. A., Tutkavul K., Ayta S., BAYKAL B., Gurses C., Gokyigit A., ÖZBEK U.
11th European Congress on Epileptology, Stockholm, Sweden, 29 June - 03 July 2014, pp.219

XLII. **Expression Levels of Local RAS in Lymphoid and Myelid Malignancies**
Çatal Tatonyn S., UZ B., SAYİTOĞLU M., ERBİLGİN Y., HATIRNAZ NG Ö., ÖZBEK U., BÜYÜKAŞIK Y., AKSU S., SAYINALP N., GÖKER H., et al.
ELN Frontiers Meeting, 09 November 2012

XLIII. **T HÜCRELİ AKUT LENFOBLASTİK LÖSEMİDE GENOM BOYU ANLATIM ANALİZLERİ**
HATIRNAZ NG Ö., SAYİTOĞLU M., ERBİLGİN Y., ÖZTUNÇ C., STAAL F., VAN DONGEN J., ÖZBEK U.
3. DETAE GÜNLERİ, Turkey, 17 - 18 November 2011

XLIV. **A new noncoding risk factor for Acute Lymphoblastic Leukemia 8q24 region preliminary data**
Can İ., HATIRNAZ NG Ö., ERBİLGİN Y., Öztunç C., SAYİTOĞLU M., ÖZBEK U.
The 3.rd EMBO meeting, 10 - 13 September 2011

XLV. **Anti-Neuronal and Stress-Induced-Phosphoprotein 1 Antibodies in Neuro-Behcet's Disease**
Akman-Demir G., Vural B., Ugurel E., Icoz S., TÜZÜN E., Kurtuncu M., Cavus F., ÖZBEK U., ERAKSOY M.
63rd AAN Annual Meeting, Hawaii, United States Of America, 9 - 16 April 2011, vol.76

XLVI. **COMPARISON OF ADIPOSE TISSUE GENE EXPRESSION OF ADIPONECTIN, TUMOR NECROSIS FACTOR-alpha AND LEPTIN IN PATIENTS WITH AND WITHOUT METABOLIC SYNDROME**
Gormez S., Demirkan A., Caynak B., Atalar F., Gunay D., Akpinar B., ÖZBEK U., Aytekin V., Yazicioglu N., Buyukdevrim A. S.
78th Congress of the European-Atherosclerosis-Society, Hamburg, Germany, 20 - 23 June 2010, vol.11, pp.20

XLVII. **Mutations in Axin1 APC and Beta catenin Genes in T cell Acute Lymphoblastic Leukemia**
SAYİTOĞLU M., ERBİLGİN Y., HATIRNAZ NG Ö., ÖZBEK U.
European School of Hematology, Scientific Workshop T-cell Acute Lymphoblastic Leukemia (T-ALL) Meets Normal T-cell Development, 7 - 09 May 2010

XLVIII. **Investigation of Bromodomain-Containing Protein 2 (BRD2) Gene Mutations in Photosensitive Epilepsy**
Baykal B., Vanli-Yavuz E. N., Ozdemir O., Catal S., Bebek N., ÖZBEK U.
62nd Annual Meeting of the American-Academy-of-Neurology, Toronto, Canada, 10 - 17 April 2010, vol.74

XLIX. **Expression Analysis of Some Candidate Genes Involved in Neurotransmission and Neurogenesis in Human Hippocampal Sclerosis**
BEBEK N., SAYİTOĞLU M., özdemir ö., Baykan B., ÖZBEK U., Karasu A., SENCER A., İzin İ., GÜRSES R. C., HATIRNAZ NG Ö., et al.
American Academy of Neurology 63nd Annual Meeting, 4 - 08 December 2009

L. **AKUT LÖSEMİLERDE ANORMAL WNT SİNYAL İLETİ YOLU AKTİVASYONU**
SAYİTOĞLU M., HATIRNAZ NG Ö., ERBİLGİN Y., SİNEM Ö., AKTAŞ ÇETİN E., MAVİ N., DENİZ G., ÖZBEK U.
1. DETAE GÜNLERİ, Turkey, 15 - 16 November 2009

LI. **Mutation Analysis of c ABL Gene in Imatinib Resistant Chronic Myeloid Leukemia Patients**
ERBİLGİN Y., Çatal S., HATIRNAZ NG Ö., SAYİTOĞLU M., SOYSAL T., ÖZBEK U.
MediMedGen Meeting, 28 June - 01 July 2009

LII. **Pax5 Expression Levels are increased in B Cell acute lymphoblastic leukemia patients**
Fırtına S., SAYİTOĞLU M., ERBİLGİN Y., Mavi N., HATIRNAZ NG Ö., ÖZBEK U.
MediMedGen Meeting, 28 June - 01 July 2009

LIII. **Mutations in Axin 1 APC and B catenin Genes in Acute Lymphoblastic Leukemia**
SAYİTOĞLU M., ERBİLGİN Y., HATIRNAZ NG Ö., Rourke E., ÖZBEK U.
MediMedGen Meeting, 28 June - 01 July 2009

LIV. **CLINICAL FEATURES OF ACUTE LYMPHOBLASTIC LEUKEMIA IN TURKISH CHILDREN RESULTS FROM A SINGLE CENTER**
İNCİ Y., DOĞRU Ö., ÖZDEMİR G. N., ÖZBEK U., CELKAN T. T., APAK H., ÖZKAN M. A.
PEDIATRIC BLOOD & CANCER, 01 January 2009

LV. **THE PROGNOSTIC SIGNIFICANCE OF GENETIC IMMUNOPHENOTYPIC AND CLINICALFEATURES OF ACUTE LYMPHOBLASTIC LEUKEMIA IN TURKISH CHILDREN RESULTSFROM A SINGLE CENTER**
İNCİ Y., DOĞRU Ö., ÖZBEK U., CELKAN T. T., APAK H., ÖZKAN M. A., ÖZDEMİR G. N.
PEDIATRIC BLOOD & CANCER, 01 January 2009

LVI. **T ALL HASTALARINDA NOTCH1 MUTASYONUNUN ARAŞTIRILMASI**
ERBİLGİN Y., SAYİTOĞLU M., HATIRNAZ Ö., YÜKSEL L., İNCİ Y., AĞAOĞLU L., ANAK S. S., AYDOĞAN G., TİMUR Ç., ÖZBEK U.
34. ULUSAL HEMATOLOJİ KONGRESİ, Turkey, 8 - 11 November 2008

LVII. **EPIGENETIC INACTIVATION OF WNT5A BY PROMOTER METHYLATION IN ACUTE LEUKEMIA PATIENTS**
ERBİLGİN Y., SAYİTOĞLU M., HATIRNAZ Ö., ÖZBEK U.
EMBO WORKSHOP ON GENOMIC IMPRINTING, 21 - 24 September 2008

LVIII. **T HÜCRELİ AKUT LENFOBLASTİK LÖSEMİ GELİŞİMİNDE ROL OYNAYAN ONKOGENİK YAZILIM FAKTÖRLERİNİN EKSPRESYONLARININ ARAŞTIRILMASI**
SAYİTOĞLU M., ERBİLGİN Y., HATIRNAZ Ö., ÖZBEK U.
8. ULUSAL TIBBİ GENETİK KONGRESİ, Turkey, 6 - 09 May 2008

LIX. **AKUT LÖSEMİ HASTALARINDA WNT SİNYAL İLETİ YOLU GENLERİNİN HİPERMETİLASYON ANALİZLERİ**
HATIRNAZ Ö., SAYİTOĞLU M., ÖZBEK U.
33. ULUSAL HEMATOLOJİ KONGRESİ, Turkey, 16 - 19 November 2007

LX. **Detection of SOCS 1 suppressor of cytokine signaling 1 methylation in CML chronic myeloid leukemia patients**
HATIRNAZ Ö., Ekmekçi C., AR M. C., ÜRE Ü. B., SOYSAL T., FERHANOĞLU A. B., ÖZBEK U.
31st FEBS Congress, 24 - 29 June 2006, vol.273

LXI. **KRONİK MYELOİD LÖSEMİ GELİİMİNDE SOCS1 GEN METİLLENMESİN**
HATIRNAZ Ö., EKMEKÇİ C. G., ÜRE Ü. B., FERHANOĞLU A. B., SOYSAL T., ÖZÇELİK H. T., ÖZBEK U.
7. ULUSAL PRENATAL TANI VE TIBBİ GENETİK KONGRESİ, Turkey, 17 - 20 May 2006

LXII. **Immunoreactivity to SOX-1,-2,-3 and ZIC2 antigens and correlation to survival in small cell lung cancer (SCLC).**
Chen L., Vural B., Ustuner Z., SAİP P. M., ÖZBEK U., Gonen M., Old L., Chen Y., Gure A.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22

LXIII. **DETOKSİFİKASYON ENZİM GEN POLİMORFİZİMLERİNİN AKUT LÖSEMİ ETİYOLOJİSİNDEKİ ROLLERİ**
SAYİTOĞLU M., HATIRNAZ Ö., ÖZBEK U.
30. ULUSAL HEMATOLOJİ KONGRESİ, Turkey, 10 - 14 November 2003

LXIV. **ALLELOTYPEFREQUENCIES OF TPMT CYP3A4 AND CYP23A5 GENES IN TURKISH POPULATION**
ÖZBEK U., SAYİTOĞLU M., HATIRNAZ Ö.
5th INTERNATIONAL SYMPOSIUM ON LEUKEMIA AND LYMPHOMA, 12 May - 15 March 2003

LXV. **Metabolising enzyme polymorphisms GSTM1 GSTT1 CYP1A1 CYP2D6 and their association as a potential susceptibility to pediatric ALL**
ÖZBEK U., SAYİTOĞLU M., HATIRNAZ NG Ö., Ağaoğlu L., SIRMA EKMEKCİ S., Yüksel L., ANAK S. S., APAK H., KARAKAŞ Z., Ünüvar A., et al.
43rd American Society of Hematology Meeting, 7 - 11 December 2001

Supported Projects

ÖZBEK U., TUBITAK Project, Sağlık Alanında İleri Analiz Teknikleri ve Hücresel Tedaviler Geliştirilmesi için Ulusal Yetkinliğin Artırılması, 2019 - 2027

BAYRAM AKÇAPINAR G., DOĞAN T., Bilgüvar K., HATIRNAZ NG Ö., ÖZBEK U., AKGÜN DOĞAN Ö., TUBITAK Project, Deep-CP: Development of a Deep Learning Variant Pathogenicity Prediction Tool using AlphaFold for Cerebral Palsy , 2022 - 2025

Alanay Y., Özbek U., Hatırnaz Ng Ö., Akgün Doğan Ö., Özdemir Ö., Çıtak A., Korkmaz Toygar A., Beken S., Kazancı E., Demirel A., et al., Project Supported by Higher Education Institutions, Yenidoğan ve Çocuk Yoğun Bakım Ünitesinde (YYBÜ/ÇYBÜ) Hızla Kötüleşen Kritik Yenidoğan ve Süt Çocuklarında Hızlı Yeni Nesil Dizileme ile Genetik Tanı, 2022 - 2024

HATIRNAZ NG Ö., ÖZDEMİR Ö., ÖZBEK U., TUBITAK Project, SARS-CoV-2 enfeksiyonuna yönelik peptid konjuge modifiye antisense morfolino oligomer tabanlı tedavi geliştirilmesi, 2021 - 2024
Sönmez Ö., Müftüoğlu M., Özbek U., Üstünyılmaz S., Manto K., Project Supported by Higher Education Institutions, Kalıtsal Kanser Sendromlu Hastalarda Klinik Önemi Belirsiz BRCA1 ve BRCA2 Varyantlarının Fonksiyonel Karakterizasyonu, 2022 - 2023
HATIRNAZ NG Ö., ÖZBEK U., X'e bağlı agamaglobulibemi'de lentiviral gen terapinin preklinik uygulamaları, 2021 - 2023
Özbek U., Alanay Y., Sezerman O. U., Julkowska D., EU Framework Program Project, European Research Program on Rare Diseases, 2019 - 2023
Üstünyılmaz S., Ağaoğlu N. B., Müftüoğlu M., Özbek U., TUBITAK Project, Kalıtsal kanserlerde klinik önemi bilinmeyen genomik varyantların fonksiyonel karakterizasyonu ve yeniden sınıflandırılması sözleşmesi, 2021 - 2022
Hatırnaz Ng Ö., Sayitoğlu M., Özbek U., Çine N., Canpolat C., Ministry of Health, TÜSEB Bireysel ve Dönüşümsel Tıp Alanındaki Uygulamalı Proje Çağrısı: Akut lenfoblastik lösemi, 2020 - 2021
Hatırnaz Ng Ö., Özbek U., Alanay Y., Research Project of the Presidency of Turkey Health Institutes (TÜSEB), Bireysel ve Dönüşümsel Tıp Alanındaki Uygulamalı Proje Çağrısı: Albinizm, 2019 - 2021

Activities in Scientific Journals

FRONTIERS IN GENETICS, Evaluation Committee Member, 2019 - Continues

Memberships / Tasks in Scientific Organizations

Rare Disease International-first workshop on Strengthening the National Healthcare Systems, Member of Science Committee, 2022 - Continues, United States Of America
Tıbbi Genetik Derneği Nadir Hastalıklar Kurulu, Chairman of the Scientific Committee, 2021 - Continues, Turkey
International Cerebral Palsy Genomic Consortium, Executive Board Member, 2020 - Continues, Australia
Türkiye Spastik Çocuklar Vakfı, Member of Science Committee, 2017 - Continues, Turkey
TÜSEB-TÜHKE, Member of Advisory Board, 2016 - Continues, Turkey
UDNI-Undiagnosed Disease Network International, Member, 2016 - Continues, United States Of America
ORPHANET, Board Member, 2009 - Continues, France
BFM Biology and Diagnosis Committee, Principal Member, 2001 - Continues, Germany
Europeand Society of Human Genetics, Member, 1989 - Continues, Belgium

Scientific Refereeing

TUBITAK Project, 1004 - Mükemmeliyet Merkezi Destek Programı FAZ I, iBG, Turkey, October 2022
H2020 Project, RIA Research and Innovation Actions Project, INSERM, France, September 2022
TUBITAK Project, 1004 - Mükemmeliyet Merkezi Destek Programı FAZ I, iBG, Turkey, April 2022
H2020 Project, RIA Research and Innovation Actions Project, INSERM, France, April 2022

Scientific Consultations

Cumhurbaşkanlığı Strateji ve Bütçe Başkanlığı, Scientific Consultancy, İstanbul Üniversitesi, Deneysel Tıp Araştırma Enstitüsü, Genetik Anabilim Dalı, Turkey, 2022 - 2023

Tasks In Event Organizations

Özbek U., UDNI meeting-November 7-8, 2022 in Vienna, Austria, Scientific Congress, Austria, Kasım 2022

Özbek U., Childhood Cancer: Causes and Epidemiology – A Course by SIOP-Europe and COST-LEGEND , Workshop Organization, Brussels, Belgium, Mayıs 2022
Özbek U., Predisposition to hereditary leukemia and lymphoma training school, Workshop Organization, Bologna, Italy, Mart 2019

Metrics

Publication: 250
Citation (WoS): 2242
Citation (Scopus): 2545
H-Index (WoS): 25
H-Index (Scopus): 26

Congress and Symposium Activities

6. Uluslararası ve 24. Ulusal Halk Sağlığı Kongresi, Invited Speaker, Antalya, Turkey, 2022
15. Uluslararası Katılımlı Ulusal Tıbbi Genetik Kongresi, Session Moderator, Muğla, Turkey, 2022
Undiagnosed Disease Network International Conferance , Attendee, Vienna, Austria, 2022
Türk Pediatrik Hematoloji Derneği Lösemi Çalıştayı, Panelists, Bursa, Turkey, 2022
"Türk Pediatrik Hematoloji Derneği Lösemi Çalıştayı, Invited Speaker, Bursa, Turkey, 2022
7. Erciyes Uluslararası Tıp Tıbbi Genetik Kongresi, Invited Speaker, Kayseri, Turkey, 2022
12. OHSAD kurultayı, Invited Speaker, Antalya, Turkey, 2022
Tıbbi Genetik Derneği Nadir Hastalıklar Günü sunumu, Invited Speaker, İstanbul, Turkey, 2022